You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Colorcon
Baxter
Medtronic
Mallinckrodt

Last Updated: February 27, 2020

DrugPatentWatch Database Preview

Rhodes Pharms Company Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for RHODES PHARMS, and when can generic versions of RHODES PHARMS drugs launch?

RHODES PHARMS has eighteen approved drugs.

There are ten US patents protecting RHODES PHARMS drugs. There is one tentative approval on RHODES PHARMS drugs.

There are forty-four patent family members on RHODES PHARMS drugs in fifteen countries and one supplementary protection certificate in one country.

Summary for Rhodes Pharms
International Patents:44
US Patents:10
Tradenames:13
Ingredients:12
NDAs:18

Drugs and US Patents for Rhodes Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rhodes Pharms ACETAMINOPHEN AND CODEINE PHOSPHATE acetaminophen; codeine phosphate TABLET;ORAL 089673-002 Feb 10, 1988 DISCN No No   Start Trial   Start Trial
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-005 Apr 17, 2015 AB3 RX Yes No 8,580,310*PED   Start Trial Y   Start Trial
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-006 Apr 17, 2015 AB3 RX Yes No 10,039,719*PED   Start Trial Y   Start Trial
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-007 Apr 17, 2015 AB3 RX Yes Yes 7,247,318*PED   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Rhodes Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-005 Apr 17, 2015 10,463,624   Start Trial
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-001 Apr 17, 2015 10,463,624   Start Trial
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-003 Apr 17, 2015 10,463,624   Start Trial
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-004 Apr 17, 2015 10,463,624   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for RHODES PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 5 mg/5mL ➤ Subscribe 2011-02-25
➤ Subscribe Tablets 2 mg, 4 mg, and 8 mg ➤ Subscribe 2013-08-05
➤ Subscribe Extended-release Capsules 10 mg ➤ Subscribe 2015-12-24
➤ Subscribe Extended-release Capsules 30 mg ➤ Subscribe 2016-03-28
➤ Subscribe Injection 2 mg/mL ➤ Subscribe 2011-06-22
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 2015-12-23
➤ Subscribe Extended-release Capsules 15 mg, 20 mg, 40 mg and 50 mg ➤ Subscribe 2015-12-28

Supplementary Protection Certificates for Rhodes Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1685839 92292 Luxembourg   Start Trial PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Colorcon
Medtronic
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.